中文

三诺生物 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-28
ItemAmountY/Y
Revenue¥1.24B+19.0%
Gross profit¥0.65B
Operating income¥0.12B
Net income¥0.10B+26.6%
Gross margin52.5%Net margin 8.3%
Revenue Q/Q+2.8%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.59B47.5%
R&D¥0.06B4.9%
SG&A¥0.44B35.5%
Tax & other¥0.01B1.2%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

富春股份海峡创新ST长方同有科技聚飞光电云意电气裕兴股份远方信息慈星股份宜通世纪ST任子行天山生物

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies